secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K/A
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001193125-24-038517
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda files financials for PONVORY acquisition; product line had $553.7M loss in FY2023 on $17.8M sales
--------------------------------------------------------------------------------

- Purchase price $100M for U.S./Canadian rights of PONVORY (ponesimod) from Johnson & Johnson.
- FY2023 net sales $17.8M, up from $3.9M in prior year; direct expenses $571.6M.
- Non-cash impairment of $426.1M on intangible asset, reducing net book value to $36.8M.
- Direct expenses exceeded sales by $553.7M; prior year excess was $160.3M.
- Vanda also filed unaudited pro forma condensed combined financials for year ended Dec 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524038517/0001193125-24-038517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524038517/d620689d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-038517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer